Novartis, Sanofi and PhRMA push FDA on how to better handle complex trial designs
Several industry stakeholders are asking the FDA to streamline its processes for working with sponsors on complex and innovative designs for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
